Ioannis Bellos, MD, National and Kapodistrian University of Athens, Greece
Lipids in Health and Disease is calling for submissions to our Collection on Lipids in Chronic Kidney Disease: Emerging Evidence and Therapeutic Perspectives. This Collection aims to bring together cutting-edge research that advances our understanding of lipid metabolism, risk stratification, and therapeutic interventions in chronic kidney disease.
Cardiovascular disease remains the leading cause of morbidity and mortality among individuals with chronic kidney disease (CKD). Both a reduced glomerular filtration rate and albuminuria substantially increase cardiovascular risk, placing patients with impaired kidney function at heightened risk for accelerated atherosclerosis, valvular heart disease, and sudden cardiac death. Despite this, clinical decision-making for both primary and secondary prevention in this population often relies on observational studies or subgroup analyses from broader trials.
Dyslipidemia is a key modifiable risk factor in this setting. CKD is typically associated with elevated triglycerides, reduced high-density lipoprotein cholesterol, and atherogenic alterations in lipoprotein composition and function. Although current guidelines support statin therapy in certain subsets of CKD patients, critical gaps remain in our understanding of optimal lipid targets, appropriate dosing strategies, and the role of emerging lipid-lowering therapies in this high-risk group.
This Collection aims to bring together cutting-edge research that advances our understanding of lipid metabolism, risk stratification, and therapeutic interventions in CKD. We welcome original research articles and high-quality meta-analyses. Priority will be given to studies evaluating hard clinical outcomes and those with the potential to inform practice or policy.
Keywords: chronic kidney disease; dyslipidemia; statin; risk stratification; cardiovascular disease
The topics of interest include but are not limited to the following:
• Lipid biomarkers for cardiovascular risk stratification in CKD patients
• Evidence-based lipid targets for patients with impaired kidney function
• Statin efficacy, safety, and dosing considerations in CKD populations
• The role of PCSK9 inhibitors in CKD and kidney transplant recipients
• Lipid management in dialysis-dependent kidney failure
• Integration of lipid-lowering therapies with novel cardiorenal protective agents, including SGLT2 inhibitors and GLP-1 receptor agonists
• Lipid-lowering strategies to slow CKD progression
• Dyslipidemia management in immunosuppressed patients with glomerular diseases or kidney transplantation
Questions to be answered:
• How is lipid metabolism altered in CKD vs. the general population?
• What is the link between dyslipidemia and cardiovascular risk in CKD?
• Which lipid markers best predict cardiovascular risk in CKD?
• Are non-traditional markers (e.g., apoB, remnant cholesterol) more useful?
• How should lipid profiles be interpreted across CKD stages?
• What are the recommended lipid targets for CKD patients?
• Should lipid targets differ by CKD stage or dialysis status?
• What’s the evidence for statin use across CKD stages?
• How should statin dosing be adjusted in renal impairment?
• When are statins not beneficial (e.g., dialysis patients)?
• What is the role of PCSK9 inhibitors in CKD and transplant populations?
• Do PCSK9 inhibitors offer renal-specific benefits?
• How do SGLT2 inhibitors & GLP-1 analogs affect lipid profiles?
• Can SGLT2 inhibitors & GLP-1 analogs be combined with statins or PCSK9 inhibitors?
• How should lipids be managed in dialysis patients?
• Can lipid-lowering improve dialysis-related outcomes?
• How do immunosuppressants impact lipid levels?
• What are the safest and most effective lipid therapies post-transplant?
• What’s the role of lipidomics, precision medicine, or genetic profiling?
• How may ongoing trials influence future guidelines?
There are currently no articles in this collection.
This Collection welcomes submissions of original research articles and high-quality meta-analyses. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal.
Articles for this Collection should be submitted via our submission system, Snapp. Please, select the appropriate Collection title “Lipids in Chronic Kidney Disease: Emerging Evidence and Therapeutic Perspectives" under the “Details” tab during the submission stage.
Articles will undergo the journal’s standard peer-review process and are subject to all the journal’s standard policies. Articles will be added to the Collection as they are published.
The Editors have no competing interests with the submissions which they handle through the peer-review process. The peer-review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.